Biosig Technologies (NASDAQ:STEX) versus Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) Head-To-Head Contrast

Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) and Biosig Technologies (NASDAQ:STEX) are both small-cap manufacturing companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Profitability

This table compares Inspira Technologies OXY B.H.N. and Biosig Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A
Biosig Technologies	N/A	-717.92%	-336.75%

Risk & Volatility

Inspira Technologies OXY B.H.N. has a beta of 4.06, meaning that its stock price is 306% more volatile than the S&P 500. Comparatively, Biosig Technologies has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Inspira Technologies OXY B.H.N. and Biosig Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspira Technologies OXY B.H.N.	1	0	0	0	1.00
Biosig Technologies	1	0	1	0	2.00

Biosig Technologies has a consensus target price of $8.00, indicating a potential upside of 842.29%. Given Biosig Technologies’ stronger consensus rating and higher probable upside, analysts plainly believe Biosig Technologies is more favorable than Inspira Technologies OXY B.H.N..

Institutional and Insider Ownership

12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are held by institutional investors. 29.4% of Inspira Technologies OXY B.H.N. shares are held by insiders. Comparatively, 52.7% of Biosig Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Inspira Technologies OXY B.H.N. and Biosig Technologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspira Technologies OXY B.H.N.	$290,000.00	174.17	-$13.22 million	N/A	N/A
Biosig Technologies	$40,000.00	3,858.71	-$462.77 million	($9.71)	-0.09

Inspira Technologies OXY B.H.N. has higher revenue and earnings than Biosig Technologies.

Summary

Inspira Technologies OXY B.H.N. beats Biosig Technologies on 6 of the 11 factors compared between the two stocks.

About Inspira Technologies OXY B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra’annana, Israel.

About Biosig Technologies

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.